Evaluating 3 Types of Targeted Therapies for Triple-Negative Breast Cancer
Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.
Aditya Bardia, MBBS, MPH, a breast medical oncologist at Massachusetts General Hospital and Harvard Medical School, discusses the development of targeted therapies for patients with triple-negative breast cancer (TNBC). He says these approaches can be divided into 3 different categories.
The first category would be targeting oncogenes. An example of this would be the use of PARP inhibitors. Second, ongoing trials are also looking at intercellular signaling pathways, says Bardia.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
